CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer.
  
  LEARNING OBJECTIVES

  • Recognize how biological and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (mUBC).
  • Determine the current clinical role of immune checkpoint inhibitors as monotherapy or as maintenance therapy after platinum-based chemotherapy for newly diagnosed mUBC.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds (eg, antibody-drug conjugates, tyrosine kinase inhibitors) with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
  • Appreciate the biological rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy for UBC, and assess the current and potential roles of these regimens in patient care.
  • Recognize the side effects and toxicities associated with recently approved and emerging systemic therapies for mUBC, and develop a plan for their management.
  • Develop an understanding of the biological rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for mUBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Terence Friedlander, MD
  Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
  Chief, Division of Hematology/Oncology
  Zuckerberg San Francisco General Hospital
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: Aadi Bioscience, Astellas, Seagen Inc; Consulting Agreement: Merck; Contracted Research: Bristol Myers Squibb, Roche Laboratories Inc, Seagen Inc, Trishula Therapeutics Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Petros Grivas, MD, PhD
  Professor, Department of Medicine
  Division of Oncology
  Clinical Director, Genitourinary Cancers Program
  University of Washington
  Professor, Clinical Research Division
  Fred Hutchinson Cancer Center
  Seattle, Washington
  
  Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis Inc, Fresenius Kabi AG, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, ImmunityBio, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lucence, Merck KgaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, PureTech Health, QED Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Silverback Therapeutics Inc, Strata Oncology, UroGen Pharma; Contracted Research: Acrivon Therapeutics Inc, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics Inc, Gilead Sciences Inc, GSK, Merck KGaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, Gilead Sciences Inc, and Merck.
  
  Release date: August 2023
  Expiration date: August 2024